ANGPTL3 Inhibitors Deliver Broad Lipid Lowering : Eur J Prev Cardiol | June 2026

Introduction:

Despite major advances in lipid-lowering therapy, many patients continue to experience residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins and mixed dyslipidemia. Angiopoietin-like protein 3 (ANGPTL3) has emerged as an attractive therapeutic target because of its central role in regulating lipid metabolism. Genetic studies have shown that reduced ANGPTL3 activity is associated with favorable lipid profiles and lower cardiovascular risk, prompting the development of several ANGPTL3-targeted therapies.

Problem Statement:

Although monoclonal antibodies, antisense oligonucleotides, and small interfering RNA therapies targeting ANGPTL3 have demonstrated promising lipid-lowering effects in individual clinical trials, the overall metabolic impact of this therapeutic class has not been comprehensively evaluated. Clarifying their efficacy across multiple lipid parameters is essential for understanding their potential role in cardiovascular risk reduction.

Summary:

This meta-analysis of randomized controlled trials provides a comprehensive assessment of the metabolic effects of ANGPTL3 inhibition. The analysis demonstrated that ANGPTL3-targeted therapies produce substantial reductions across a broad range of atherogenic lipoproteins, with particularly pronounced effects on triglyceride-rich lipoproteins. Significant improvements were observed in triglycerides, low-density lipoprotein cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, remnant cholesterol, and total cholesterol. Modest reductions were also noted in lipoprotein(a), an increasingly recognized cardiovascular risk factor. Importantly, ANGPTL3 inhibition achieved marked suppression of circulating ANGPTL3 levels, confirming effective target engagement. Differences among therapeutic approaches were observed, with the monoclonal antibody evinacumab demonstrating stronger reductions in several cholesterol-related parameters, while small interfering RNA agents showed particularly favorable effects on triglyceride-rich lipoproteins. Notably, no meaningful impact on systemic inflammatory markers was identified, suggesting that the benefits of ANGPTL3 inhibition are primarily mediated through lipid modification rather than anti-inflammatory mechanisms. These findings position ANGPTL3 inhibition as a promising strategy for patients with persistent dyslipidemia and residual cardiovascular risk, particularly those with elevated triglyceride-rich lipoproteins. Future outcome-driven studies will be essential to determine whether these impressive lipid improvements translate into meaningful reductions in cardiovascular events and long-term clinical benefit.